S&P 500   3,852.36
DOW   32,920.46
QQQ   296.26
Is Buying an Aged Corporation a Good Idea?
The Next Big Crisis Is Here (Ad)
Lots of sound and fury on US debt, but not a crisis — yet
Italy, Libya sign $8B gas deal as PM Meloni visits Tripoli
The Next Big Crisis Is Here (Ad)
Online system to seek asylum in US is quickly overwhelmed
Challenge for Tunisian democracy: Getting voters to show up
The Next Big Crisis Is Here (Ad)
Is tipping getting out of control? Many consumers say yes
FTX's Sam Bankman-Fried, DOJ tussle over his communications
S&P 500   3,852.36
DOW   32,920.46
QQQ   296.26
Is Buying an Aged Corporation a Good Idea?
The Next Big Crisis Is Here (Ad)
Lots of sound and fury on US debt, but not a crisis — yet
Italy, Libya sign $8B gas deal as PM Meloni visits Tripoli
The Next Big Crisis Is Here (Ad)
Online system to seek asylum in US is quickly overwhelmed
Challenge for Tunisian democracy: Getting voters to show up
The Next Big Crisis Is Here (Ad)
Is tipping getting out of control? Many consumers say yes
FTX's Sam Bankman-Fried, DOJ tussle over his communications
S&P 500   3,852.36
DOW   32,920.46
QQQ   296.26
Is Buying an Aged Corporation a Good Idea?
The Next Big Crisis Is Here (Ad)
Lots of sound and fury on US debt, but not a crisis — yet
Italy, Libya sign $8B gas deal as PM Meloni visits Tripoli
The Next Big Crisis Is Here (Ad)
Online system to seek asylum in US is quickly overwhelmed
Challenge for Tunisian democracy: Getting voters to show up
The Next Big Crisis Is Here (Ad)
Is tipping getting out of control? Many consumers say yes
FTX's Sam Bankman-Fried, DOJ tussle over his communications
S&P 500   3,852.36
DOW   32,920.46
QQQ   296.26
Is Buying an Aged Corporation a Good Idea?
The Next Big Crisis Is Here (Ad)
Lots of sound and fury on US debt, but not a crisis — yet
Italy, Libya sign $8B gas deal as PM Meloni visits Tripoli
The Next Big Crisis Is Here (Ad)
Online system to seek asylum in US is quickly overwhelmed
Challenge for Tunisian democracy: Getting voters to show up
The Next Big Crisis Is Here (Ad)
Is tipping getting out of control? Many consumers say yes
FTX's Sam Bankman-Fried, DOJ tussle over his communications
NASDAQ:CASI

CASI Pharmaceuticals - CASI Stock Forecast, Price & News

$2.04
+0.05 (+2.51%)
(As of 01/27/2023 12:00 AM ET)
Add
Compare
Today's Range
$2.02
$2.05
50-Day Range
$1.48
$2.08
52-Week Range
$1.45
$10.30
Volume
12,233 shs
Average Volume
32,860 shs
Market Capitalization
$27.76 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$10.00

CASI Pharmaceuticals MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
390.2% Upside
$10.00 Price Target
Short Interest
Healthy
2.13% of Float Sold Short
Dividend Strength
N/A
Sustainability
-1.50
Upright™ Environmental Score
News Sentiment
0.96mentions of CASI Pharmaceuticals in the last 14 days
Based on 3 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($2.16) to ($2.05) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.63 out of 5 stars

Medical Sector

104th out of 1,054 stocks

Biological Products, Except Diagnostic Industry

20th out of 170 stocks


CASI stock logo

About CASI Pharmaceuticals (NASDAQ:CASI) Stock

CASI Pharmaceuticals, Inc. is a biopharmaceutical company, which is focused on the acquisition, development and commercialization of therapeutics addressing cancer and other unmet medical needs. The company develops and commercializes the oncology drugs and drug candidates in China, Taiwan, Hong Kong, and Macau. Its products include Zevalin, Evomela, and Marqibo. The company was founded in 1991 and is headquartered in Rockville, MD.

Receive CASI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for CASI Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

CASI Stock News Headlines

The Next Big Crisis Is Here
You just can’t see it yet because it’s NOT a banking, financial, or economic crisis… it’s far worse and threatens every dollar in your retirement account.
Is This The End of Capitalism?
EXPOSED: The establishment plot to disenfranchise and impoverish millions of Americans…
Casi Pharmaceuticals
Wednesday 9/7 Insider Buying Report: JELD, CASI
See More Headlines
Receive CASI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for CASI Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

CASI Company Calendar

Last Earnings
11/14/2022
Today
1/29/2023
Next Earnings (Estimated)
3/27/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:CASI
Employees
176
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$10.00
High Stock Price Forecast
$10.00
Low Stock Price Forecast
$10.00
Forecasted Upside/Downside
+390.2%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
2 Analysts

Profitability

Net Income
$-36,650,000.00
Pretax Margin
-71.10%

Debt

Sales & Book Value

Annual Sales
$30.17 million
Book Value
$6.04 per share

Miscellaneous

Free Float
9,988,000
Market Cap
$27.76 million
Optionable
Not Optionable
Beta
0.39

Key Executives

  • Wei-Wu HeWei-Wu He
    Executive Chairman & Chief Executive Officer
  • Wei Zhang
    President
  • Cynthia Wong Hu
    COO, Secretary & General Counsel
  • Wei Hao Xu
    Chief Financial Officer
  • Alexander A. Zukiwski
    Chief Medical Officer













CASI Stock - Frequently Asked Questions

Should I buy or sell CASI Pharmaceuticals stock right now?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for CASI Pharmaceuticals in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" CASI shares.
View CASI analyst ratings
or view top-rated stocks.

What is CASI Pharmaceuticals' stock price forecast for 2023?

2 Wall Street research analysts have issued 1-year target prices for CASI Pharmaceuticals' shares. Their CASI share price forecasts range from $10.00 to $10.00. On average, they predict the company's share price to reach $10.00 in the next twelve months. This suggests a possible upside of 390.2% from the stock's current price.
View analysts price targets for CASI
or view top-rated stocks among Wall Street analysts.

How have CASI shares performed in 2023?

CASI Pharmaceuticals' stock was trading at $1.79 at the beginning of 2023. Since then, CASI stock has increased by 14.0% and is now trading at $2.04.
View the best growth stocks for 2023 here
.

Are investors shorting CASI Pharmaceuticals?

CASI Pharmaceuticals saw a decrease in short interest during the month of January. As of January 15th, there was short interest totaling 277,800 shares, a decrease of 5.9% from the December 31st total of 295,200 shares. Based on an average trading volume of 33,900 shares, the days-to-cover ratio is presently 8.2 days. Approximately 2.1% of the company's stock are sold short.
View CASI Pharmaceuticals' Short Interest
.

When is CASI Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, March 27th 2023.
View our CASI earnings forecast
.

How were CASI Pharmaceuticals' earnings last quarter?

CASI Pharmaceuticals, Inc. (NASDAQ:CASI) announced its earnings results on Monday, November, 14th. The biotechnology company reported ($0.38) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.51) by $0.13. The biotechnology company earned $10.21 million during the quarter, compared to analyst estimates of $10.40 million. CASI Pharmaceuticals had a negative trailing twelve-month return on equity of 37.59% and a negative net margin of 73.17%.

When did CASI Pharmaceuticals' stock split?

CASI Pharmaceuticals shares reverse split before market open on Wednesday, June 1st 2022. The 1-10 reverse split was announced on Wednesday, June 1st 2022. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, June 1st 2022. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

What other stocks do shareholders of CASI Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other CASI Pharmaceuticals investors own include NVIDIA (NVDA), OPKO Health (OPK), Caladrius Biosciences (CLBS), Overstock.com (OSTK), Riot Blockchain (RIOT), Boeing (BA), Enphase Energy (ENPH), Catalyst Pharmaceuticals (CPRX), Pure Storage (PSTG) and QUALCOMM (QCOM).

What is CASI Pharmaceuticals' stock symbol?

CASI Pharmaceuticals trades on the NASDAQ under the ticker symbol "CASI."

How do I buy shares of CASI Pharmaceuticals?

Shares of CASI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is CASI Pharmaceuticals' stock price today?

One share of CASI stock can currently be purchased for approximately $2.04.

How much money does CASI Pharmaceuticals make?

CASI Pharmaceuticals (NASDAQ:CASI) has a market capitalization of $27.76 million and generates $30.17 million in revenue each year. The biotechnology company earns $-36,650,000.00 in net income (profit) each year or ($1.94) on an earnings per share basis.

How many employees does CASI Pharmaceuticals have?

The company employs 176 workers across the globe.

How can I contact CASI Pharmaceuticals?

CASI Pharmaceuticals' mailing address is 9620 MEDICAL CENTER DR STE 300, ROCKVILLE MD, 20850. The official website for the company is www.casipharmaceuticals.com. The biotechnology company can be reached via phone at (240) 864-2600, via email at ir@casipharmaceuticals.com, or via fax at 301-315-2437.

This page (NASDAQ:CASI) was last updated on 1/29/2023 by MarketBeat.com Staff